公开(公告)号：US20210153535A1

公开(公告)日：2021-05-27

申请号：US17051653

申请日：2019-05-01

Applicant: Chr. Hansen A/S

Inventor： Brynjulf MORTENSEN ,  Anders DAMHOLT ,  Anja WELLEJUS ,  Vibeke WESTPHAL STENNICKE ,  Johan E. T. VAN HYCKLAMA VLIEG

IPC: A23L33/135 ,  A61K35/745 ,  A61K45/06 ,  A61P1/00

Abstract: The present invention relates to Bifidobacterium breve deposited as DSM 32356 and compositions comprising said strain. The composition may further comprise at least one other bacterial strain and/or at least one compound which may be an NSAID such as acetylsalicylic acid (aspirin). In a presently preferred embodiment the invention relates to Bifidobacterium breve deposited as DSM 32356 for use in the support of the defense against intestinal tissue damage such as intestinal mucosal breaks or lesions e.g. in connection with NSAID administration such as in connection with administration of acetylsalicylic acid (aspirin). The invention further provides a method of supporting the defense against intestinal tissue damage, the method comprising administering the Bifidobacterium breve strain deposited as DSM 32356 to a subject in need thereof, e.g. to a subject in need of NSAID treatment.